These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 25372847)

  • 21. Efficacy and safety of once-weekly dulaglutide in adult Chinese patients with type 2 diabetes and lower baseline body mass index.
    Shi Y; Liu S; Zhu J; Hong T
    J Diabetes; 2021 Apr; 13(4):353-357. PubMed ID: 33325105
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Total cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trail: a post hoc analysis.
    Dagenais GR; Rydén L; Leiter LA; Lakshmanan M; Dyal L; Probstfield JL; Atisso CM; Shaw JE; Conget I; Cushman WC; Lopez-Jaramillo P; Lanas F; Munoz EGC; Pirags V; Pogosova N; Basile J; Sheu WHH; Temelkova-Kurktschiev T; Raubenheimer PJ; Keltai M; Hall S; Pais P; Colhoun HM; Riddle MC; Gerstein HC
    Cardiovasc Diabetol; 2020 Nov; 19(1):199. PubMed ID: 33239067
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-acting GLP-1 receptor agonists: Findings and implications of cardiovascular outcomes trials.
    Urquhart S; Willis S
    JAAPA; 2020 Aug; 33(8):19-30. PubMed ID: 32740122
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dulaglutide for the treatment of type 2 diabetes.
    Amblee A
    Drugs Today (Barc); 2014 Apr; 50(4):277-89. PubMed ID: 24918645
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New drugs: dulaglutide, olodaterol hydrochloride, and vorapaxar sulfate.
    Hussar DA; Wetty DR
    J Am Pharm Assoc (2003); 2015; 55(1):106, 108-10. PubMed ID: 25575154
    [No Abstract]   [Full Text] [Related]  

  • 26. Dulaglutide: first global approval.
    Sanford M
    Drugs; 2014 Nov; 74(17):2097-103. PubMed ID: 25367716
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative Meta-Analysis of Retatrutide Versus Placebo and Dulaglutide for Weight Loss and Diabetes Management: Insights From Clinical Trials.
    Ayesh H; Ayesh S; Niswender K
    Am J Ther; 2024 Jul-Aug 01; 31(4):e523-e527. PubMed ID: 38976545
    [No Abstract]   [Full Text] [Related]  

  • 28. Safe and Effective Use of the Once Weekly Dulaglutide Single-Dose Pen in Injection-Naïve Patients With Type 2 Diabetes.
    Matfin G; Van Brunt K; Zimmermann AG; Threlkeld R; Ignaut DA
    J Diabetes Sci Technol; 2015 Apr; 9(5):1071-9. PubMed ID: 25901022
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Cardiac Disorders.
    Wroge J; Williams NT
    Ann Pharmacother; 2016 Dec; 50(12):1041-1050. PubMed ID: 27531946
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Pharmacological profile and clinical trial results of a long-acting, once weekly human GLP-1 receptor agonist Dulaglutide (Genetical Recombination)].
    Tamaki C; Takeuchi M; Iwamoto N; Glaesner W
    Nihon Yakurigaku Zasshi; 2015 Oct; 146(4):215-24. PubMed ID: 26656966
    [No Abstract]   [Full Text] [Related]  

  • 31. Recent progress and future options in the development of GLP-1 receptor agonists for the treatment of diabesity.
    Lorenz M; Evers A; Wagner M
    Bioorg Med Chem Lett; 2013 Jul; 23(14):4011-8. PubMed ID: 23743288
    [TBL] [Abstract][Full Text] [Related]  

  • 32. GLP-1R agonist therapy for diabetes: benefits and potential risks.
    Samson SL; Garber A
    Curr Opin Endocrinol Diabetes Obes; 2013 Apr; 20(2):87-97. PubMed ID: 23403741
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ACP Journal Club: in metformin-treated type 2 diabetes mellitus, weekly dulaglutide was noninferior to daily liraglutide for HbA1c levels.
    Morey-Vargas OL; Shah P
    Ann Intern Med; 2014 Nov; 161(10):JC9. PubMed ID: 25402542
    [No Abstract]   [Full Text] [Related]  

  • 34. Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes: a pre-specified meta-analysis of prospectively adjudicated cardiovascular events.
    Ferdinand KC; Botros FT; Atisso CM; Sager PT
    Cardiovasc Diabetol; 2016 Feb; 15():38. PubMed ID: 26912057
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Clinical Overview of Once-weekly Glucagon-like Peptide-1 Receptor Agonists.
    Unger J
    J Fam Pract; 2018 Jun; 67(6 suppl):S1-S2. PubMed ID: 29912994
    [No Abstract]   [Full Text] [Related]  

  • 36. The effects of LY2189265, a long-acting glucagon-like peptide-1 analogue, in a randomized, placebo-controlled, double-blind study of overweight/obese patients with type 2 diabetes: the EGO study.
    Umpierrez GE; Blevins T; Rosenstock J; Cheng C; Anderson JH; Bastyr EJ;
    Diabetes Obes Metab; 2011 May; 13(5):418-25. PubMed ID: 21251180
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Albiglutide: a new GLP-1 analog for the treatment of type 2 diabetes.
    St Onge EL; Miller SA
    Expert Opin Biol Ther; 2010 May; 10(5):801-6. PubMed ID: 20367248
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The safety and tolerability of GLP-1 receptor agonists in the treatment of type 2 diabetes: a review.
    Aroda VR; Ratner R
    Diabetes Metab Res Rev; 2011 Sep; 27(6):528-42. PubMed ID: 21484979
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Generalizability of results from the recent FDA-guided cardiovascular outcomes trials to a representative population with Type 2 Diabetes attending primary care clinics.
    Vinagre I; Gerstein H; Viñals C; Conget I
    Endocrinol Diabetes Nutr (Engl Ed); 2019; 66(7):467-468. PubMed ID: 30890422
    [No Abstract]   [Full Text] [Related]  

  • 40. DR10601, a novel recombinant long-acting dual glucagon-like peptide-1 and glucagon receptor agonist for the treatment of obesity and type 2 diabetes mellitus.
    Wang W; Wen X; Duan W; Wang X; Chen Y; Dong J; Yang Z; Fang J; Zhou Z; Yao G; Fang Y; Huang Y
    J Endocrinol Invest; 2020 May; 43(5):653-662. PubMed ID: 31786794
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.